In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...
Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
The clinical trial results of India’s first CAR T-cell therapy, published in The Lancet, show that it worked for nearly 73 ...
Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen ...
A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...
Scientists may have unlocked a new milestone in cancer treatment. An individual who received CAR T-cell therapy has been in ...
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.
X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...
Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results